E. Kwon

Cancer Research · 2000–2017

A researcher in the Science corpus: 5 papers; trusts 0 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Papers from E. Kwon's perspective

Ordered by how strongly the researchers E. Kwon trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma (New England Journal of Medicine)
  2. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. (Journal of Clinical Oncology)
  3. Enzalutamide in Metastatic Prostate Cancer before Chemotherapy (New England Journal of Medicine)
  4. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised,… (The Lancet Oncology)
  5. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. (New England Journal of Medicine)
  6. Management of immune-related adverse events and kinetics of response with ipilimumab. (Journal of Clinical Oncology)
  7. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. (The Lancet Oncology)
  8. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. (The Lancet)
  9. Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity (Nature Medicine)
  10. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. (The Lancet Oncology)

Their papers